Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. - sprookjes - yvandenbroek - TriplyDB

Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

http://www.wikidata.org/entity/Q47563168

about

Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance Immuno-intervention for the induction of transplantation tolerance through mixed chimerism Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression Donor bone marrow-derived T cells inhibit GVHD induced by donor lymphocyte infusion in established mixed allogeneic hematopoietic chimeras.Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism.MDcons: Intermolecular contact maps as a tool to analyze the interface of protein complexes from molecular dynamics trajectories Emerging therapies for graft-versus-host disease.The clinical application of monoclonal antibody therapies in renal transplantation.Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions Cellular immune therapy for refractory cancers: novel therapeutic strategies.Treatment of severe autoimmune disease by stem-cell transplantation.Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning.Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli.Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review.Immune tolerance: mechanisms and application in clinical transplantation.HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Haploidentical hematopoietic cell transplantation.Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.The great debate: haploidentical or cord blood transplant.Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.Emerging concepts in haematopoietic cell transplantation.The expanding frontier of hematopoietic cell transplantation.Induction of tolerance through mixed chimerism.Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.Avoiding immunological rejection in regenerative medicine.The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.Immune tolerance in recipients of combined haploidentical bone marrow and kidney transplantation.Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in naïve baboons.Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.Rapid lymphocyte reconstitution of unconditioned immunodeficient mice with non-self-renewing multipotent hematopoietic progenitors.Mechanisms of transplantation tolerance in animals and humans.Sirolimus in unmanipulated haploidentical cell transplantation.

P2860

Q26745435-F2141981-3190-496F-8922-31AB1DF0170E Q27001243-4153C739-8A5B-4045-87E6-9D77A8E1341F Q33841389-57A05D1E-FFD6-4CAE-B64D-01DCD83B944E Q34175958-B1A7CCD2-99D9-4637-A421-09F71DF43EE4 Q34450566-4F451887-AE63-4462-86CA-0A21A5FFD532 Q35149926-9CC82F41-5DF9-40A6-ADD4-C393B78CF7C5 Q35215905-B7916B0E-2BB4-4C3C-B51F-072796B01361 Q35602633-05EA3274-8312-4186-AD2C-1D24588A3F83 Q35779272-DD82B051-2CBC-4E72-B807-FD4C89CE595C Q35849099-D1DA3CD1-6778-4EC5-BC80-804DD9451FC0 Q36003215-87D47B8C-39A0-4176-B91E-D8767D340308 Q36148421-D1A037E8-CCF3-4917-9848-D1C191CF7D4C Q36227853-763023C6-D6B4-45A9-82AC-DDD282514891 Q36474155-29767901-88A0-4320-AD61-9323FA1889FA Q36488985-79D13A9E-27D8-4421-8171-3EF52C813C50 Q36548362-43FBC6E6-7F9A-4788-ADAE-A47326974483 Q36580788-04CB4D04-BF83-40BE-9A39-3346153F61A8 Q36909564-E25D43A5-A6BB-4233-882C-5C0849EA521E Q37078261-8C568688-B4B7-4E95-A234-28EDF3D3EED3 Q37157971-33BB4115-BB56-4EC8-9A14-ADEC07B6699E Q37176587-CA9CB86B-7559-408E-B6CD-B1E7B696A29C Q37211290-2E697031-7122-49F8-9B86-80D9ABF57D9A Q37251055-D1B11089-1E5F-4D51-AA89-07C4843A020F Q37388414-AD3009A4-8E76-4B69-8720-239BCF0A1370 Q37694772-AE986E85-61A3-42ED-B558-B10B780A681E Q37806066-1DC95546-07C5-4267-B3B2-CF73C296EF7C Q37894465-DC9E19B1-6E01-4734-8B07-533846E26DF5 Q38013047-F9ECB303-691A-4C44-AD00-5F586F61C9AB Q38032255-94117989-ADE2-4733-88D4-87AF6B6993FF Q38175306-85378EA3-41E7-4E9E-9D4D-009D3AF0AD32 Q38374072-6A2D1A9F-C4AE-4028-ADA2-CD07B3B1365D Q38453650-8AA03F27-B2B8-4763-8074-F4FEF08A5183 Q38514485-DFA1208A-5FE1-4D3C-83CB-9A7D39FE9D8D Q38514510-8082453F-58FA-4E21-84C5-4D5E18F1336A Q40382580-476B7565-05F5-4E5B-AC2F-2CAA1F4C09CB Q41985264-9C1E69D7-1E46-4022-8F6A-D51E9361126A Q42028666-86A6F9A7-250E-40A8-A99A-5623A12EA662 Q42209021-E52A3F1A-5EE4-478C-B730-FF5A79BFB473 Q42699024-4AC4376E-587C-4A7A-9BB6-F07F0E9544FE Q46434557-663D942B-E9EC-47C2-B4D8-F5EE92A119CD

P2860

Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

http://www.wikidata.org/entity/Q47563168

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Nonmyeloablative haploidentica ...... tory hematologic malignancies.

@en

Nonmyeloablative haploidentica ...... g anti-CD2 monoclonal antibody

@nl

type

label

Nonmyeloablative haploidentica ...... tory hematologic malignancies.

@en

Nonmyeloablative haploidentica ...... g anti-CD2 monoclonal antibody

@nl

prefLabel

Nonmyeloablative haploidentica ...... tory hematologic malignancies.

@en

Nonmyeloablative haploidentica ...... g anti-CD2 monoclonal antibody

@nl

P1433

Q47563168-C21764E1-FF47-46BC-8C62-247B3F7A25CD

P1476

Q47563168-871C16BF-97E8-4E80-9E40-7B96A08113FC

P2093

Q47563168-1CDAFC38-7740-4196-9651-5F7EE20860E8

Q47563168-26EB91E2-0BBD-40E9-9A03-37FABE5D4235

Q47563168-3F1457B8-A209-44FF-8245-806A38997907

Q47563168-79470DAA-C207-4A82-8850-13B5CE3388FC

Q47563168-7A3315B0-D430-4201-8E96-EF38C365FF3D

Q47563168-9A03CCAD-4C62-4A84-A543-2E9586158178

Q47563168-AF4F1947-FD35-4D2F-B76A-4CCE13FC3689

Q47563168-B1D6EF99-DB11-4FF9-ACD4-F063F2F8DAD8

Q47563168-D1FF6A34-59A8-48DB-8C63-0223BD62DECD

Q47563168-DFD2793D-8FBD-4123-B9C0-D16CDFD8AFCD

P304

Q47563168-461F8E5C-CB24-489A-933E-4D59214093FE

P31

Q47563168-5B8F941A-B256-4445-8AA4-5D4B8CBF94B0

P356

Q47563168-C115984D-BCE7-4729-81D4-5F029A7A61F1

P433

Q47563168-953D405C-88FA-44D3-9C80-6542EC495894

P478

Q47563168-C7BA66A0-7D93-4F9E-9289-D4A9B570FAAB

P577

Q47563168-B5F3FA34-5F33-480A-A588-69428808E4E8

P698

Q47563168-0D53BCE3-2956-4B38-B1CD-DB9AAB612A85

P921

Q47563168-A7007E29-65DC-40A6-B3F2-2EBC351329E8

P356

01.TP.0000064211.23536.AD

P1433

Transplantation

P1476

Nonmyeloablative haploidentica ...... tory hematologic malignancies.

@en

P2093

Bimalangshu R Dey

http://www.w3.org/2001/XMLSchema#string

Christine Colby

http://www.w3.org/2001/XMLSchema#string

David H Sachs

http://www.w3.org/2001/XMLSchema#string

Frederic Preffer

http://www.w3.org/2001/XMLSchema#string

Howard Grossberg

http://www.w3.org/2001/XMLSchema#string

James Hope

http://www.w3.org/2001/XMLSchema#string

Juanita Shaffer

http://www.w3.org/2001/XMLSchema#string

Megan Sykes

http://www.w3.org/2001/XMLSchema#string

Stephen I Alexander

http://www.w3.org/2001/XMLSchema#string

Steven L McAfee

http://www.w3.org/2001/XMLSchema#string

P304

1748-1751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.TP.0000064211.23536.AD

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12777868

http://www.w3.org/2001/XMLSchema#string

P921